Get access

Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma

Authors

  • J. H. Burton,

    Corresponding author
    1. Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
    • Correspondence address:

      Dr Jenna H. Burton,

      Deparment of Clinical Sciences

      Colorado State University

      300 W Drake Road

      Fort Collins, CO 80523, USA

      e-mail: jhburton@colostate.edu

    Search for more papers by this author
  • E. Garrett-Mayer,

    1. Hollings Cancer Center, Department of Medicine, Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, SC, USA
    Search for more papers by this author
  • D. H. Thamm

    1. Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
    Search for more papers by this author

Abstract

Dose intense CHOP protocols have been shown to improve outcome for people with non-Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Thirty-one client owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression-free interval (PFI) of 140 days [95% confidence interval (CI) 91–335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.

Ancillary